• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Market Access Brazil: Unlocking Pharma Potential. Product Image

Market Access Brazil: Unlocking Pharma Potential.

  • Published: July 2011
  • Region: Brazil
  • 38 Pages
  • FirstWord Publishing


  • Aché
  • Amgen
  • Bristol-Myers Squibb
  • Eurofarma
  • Novartis
  • Roche
  • MORE

With this year’s election of president Dilma Rousseff, Brazil has indicated a willingness to encourage long-term foreign investment in the pharmaceutical industry. Yet while Rousseff has set three critical path priorities to ensure investment flows into the country, there are serious concerns. Price setting, the ‘big stick’ of the compulsory licenses, burdensome tax laws, slow product approvals and linguistic barriers have all emerged as key issues. Complicating matters is competition from government-favoured generics and a high volume in illegally-traded drugs, which represent 25 percent of all pharmaceuticals sold.

Yet while those issues may seem insurmountable, gaining access to the fast-growing and potentially rich Brazilian market is not impossible—with the right information.

Report Overview

Market Access Brazil: Unlocking Pharma Potential lays bare the otherwise complex operations of the Brazilian health industry. From an examination of health care responsibilities and the role of the National Health Surveillance Agency (ANVISA) to consumer trends, the latest patent protection issues, the role of generics and ongoing battle over intellectual READ MORE >

Executive summary


The Brazilian pharmaceutical market
- Healthcare provision
- Health sector responsibilities
- Principal pharmaceutical patent legislation
- Patent protection
- Pharmaceutical patent applications
(Jan 2001-Jan 2011)
- Accessing the Brazilian pharmaceutical market

Trends in the Brazilian pharmaceutical market
- Prescription Data for Brazil, 2009/10
- Pharmaceuticals in Brazil, User Profile
- Pharmaceutical Production in Brazil by Type of Capital, 2010
- Intellectual Property
- Generics
- Estimated Market Shares of the Top 10 Pharma Companies in Brazil, June 2011
- Licensing agreements
- Measures to ensure the legality of medicines in Brazil
- Interview with Marin Osorio, Senior Secretary, Ministry of Health
- Price control
- New reimbursement legislation
- Multiple trade marks
- The 'Pipeline Mechanism'
- Investing within a protectionist environment
- Establishing a presence in Brazil
- The Brazilian market in comparative perspective
- Pharma sector competitive infrastructure index in Latin American markets (June 2010)
- Latin American pharmaceutical market sizes: Estimates and forecasts, 2009-14
- Latin American agreements influencing Brazil's pharma industry

Company Updates
- The Brazilian pharmaceutical market: Some recent deals
- Aché
- Amgen
- Bristol-Myers Squibb
- Eurofarma
- Novartis
- Roche

- Aché
- Amgen
- Bristol-Myers Squibb
- Eurofarma
- Novartis
- Roche

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos